Haiyi Guo

2.0k total citations
28 papers, 1.3k citations indexed

About

Haiyi Guo is a scholar working on Genetics, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Haiyi Guo has authored 28 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 14 papers in Oncology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Haiyi Guo's work include Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (13 papers) and Cancer Treatment and Pharmacology (6 papers). Haiyi Guo is often cited by papers focused on Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (13 papers) and Cancer Treatment and Pharmacology (6 papers). Haiyi Guo collaborates with scholars based in China, United States and Australia. Haiyi Guo's co-authors include Fangfang Lü, Chengying Xie, Yongping Xu, Haitian Quan, Liguang Lou, Jin Li, Shu Tian, Fangfang Lv, Jane Huang and Jianfeng Zhou and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Haiyi Guo

28 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Haiyi Guo China	12	743	447	429	350	318	28	1.3k
Xiaonan Hong China	20	1.0k 1.4×	930 2.1×	416 1.0×	248 0.7×	309 1.0×	71	1.7k
Enrico Derenzini Italy	25	766 1.0×	1.2k 2.7×	275 0.6×	405 1.2×	344 1.1×	99	1.9k
Wendy Walsh Canada	17	639 0.9×	210 0.5×	310 0.7×	608 1.7×	226 0.7×	29	1.4k
Maja J.A. de Jonge Netherlands	19	848 1.1×	195 0.4×	420 1.0×	865 2.5×	170 0.5×	40	1.6k
Dana S. Thompson United States	21	1.0k 1.4×	335 0.7×	442 1.0×	507 1.4×	98 0.3×	75	1.5k
Lynn Navale United States	17	1.7k 2.2×	863 1.9×	241 0.6×	387 1.1×	212 0.7×	59	2.1k
Fangfang Lv China	14	432 0.6×	275 0.6×	225 0.5×	215 0.6×	139 0.4×	65	840
Martin Kornacker Germany	20	564 0.8×	317 0.7×	160 0.4×	380 1.1×	299 0.9×	59	1.3k
Patricia Marinello United States	21	1.5k 2.0×	704 1.6×	314 0.7×	345 1.0×	153 0.5×	90	1.9k
Martin Poleski United States	12	548 0.7×	176 0.4×	192 0.4×	357 1.0×	231 0.7×	18	1.2k

Countries citing papers authored by Haiyi Guo

Since Specialization

Citations

This map shows the geographic impact of Haiyi Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haiyi Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haiyi Guo more than expected).

Fields of papers citing papers by Haiyi Guo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haiyi Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haiyi Guo. The network helps show where Haiyi Guo may publish in the future.

Co-authorship network of co-authors of Haiyi Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Haiyi Guo. A scholar is included among the top collaborators of Haiyi Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haiyi Guo. Haiyi Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Opat, Stephen, John Hrom, David Kliman, et al.. (2024). BGB-11417-203: An ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia.. Journal of Clinical Oncology. 42(16_suppl). TPS7090–TPS7090. 3 indexed citations

Opat, Stephen, John Hrom, David Kliman, et al.. (2024). BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia. Blood. 144(Supplement 1). 1661.1–1661.1. 1 indexed citations

Soumerai, Jacob D., Chan Y. Cheah, Mary Ann Anderson, et al.. (2024). Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101. Blood. 144(Supplement 1). 1012–1012. 7 indexed citations

An, Gang, Daobin Zhou, Shu Cheng, et al.. (2021). A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. Clinical Cancer Research. 27(20). 5492–5501. 25 indexed citations

Song, Yuqin, Quanli Gao, Huilai Zhang, et al.. (2021). Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.. Journal of Clinical Oncology. 39(15_suppl). e19507–e19507. 1 indexed citations

Yang, Haiyan, Bing Xiang, Yuqin Song, et al.. (2021). Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma. Blood Advances. 6(6). 1629–1636. 34 indexed citations

Song, Yuqin, Keshu Zhou, Dehui Zou, et al.. (2020). Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clinical Cancer Research. 26(16). 4216–4224. 111 indexed citations

Xu, Wei, Shenmiao Yang, Keshu Zhou, et al.. (2020). Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. Journal of Hematology & Oncology. 13(1). 48–48. 92 indexed citations

Chen, Wei, et al.. (2020). Protective Effect of Vitamin C against Infancy Rat Corneal Injury Caused by Acute UVB Irradiation. BioMed Research International. 2020(1). 8089273–8089273. 11 indexed citations

10.

Yang, Haiyan, Bing Xiang, Yuqin Song, et al.. (2020). Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: Results from a phase II, single-arm, multicenter, study.. Journal of Clinical Oncology. 38(15_suppl). e20051–e20051. 3 indexed citations

11.

Song, Yuqin, Quanli Gao, Huilai Zhang, et al.. (2019). Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia. 34(2). 533–542. 108 indexed citations

12.

Farrell, Colm, et al.. (2015). Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia. Clinical Therapeutics. 37(7). 1382–1395. 10 indexed citations

13.

Yang, Renchi, Ming Hou, Junmin Li, et al.. (2014). Effect of Eltrombopag on Platelet Response and Safety Results in Chinese Adults with Chronic ITP-Primary Result of a Phase III Study. Blood. 124(21). 1464–1464. 8 indexed citations

14.

Zhang, Jian, Yu Gan, Zhonghua Wang, et al.. (2012). Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?. Cancer Chemotherapy and Pharmacology. 71(1). 103–113. 9 indexed citations

15.

Tian, Shu, Haitian Quan, Chengying Xie, et al.. (2011). YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Science. 102(7). 1374–1380. 436 indexed citations

16.

Wang, Leiping, Qunling Zhang, Jian Zhang, et al.. (2011). PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer. 11(1). 248–248. 109 indexed citations

17.

Jin, Li, Xinmin Zhao, Lei Chen, et al.. (2010). Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 10(1). 529–529. 219 indexed citations

18.

Zhao, Xinmin, Xiaofeng Xu, Lin Guo, et al.. (2010). Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. Breast Cancer Research and Treatment. 124(3). 733–743. 27 indexed citations

19.

Chang, Jianhua, Xianghua Wu, Ye Guo, et al.. (2009). A phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: Armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biology & Therapy. 8(8). 676–682. 66 indexed citations

20.

Hu, Xichun, et al.. (2006). Phase II study of mitomycin C and cisplatin in heavily pretreated advanced breast cancer. The Chinese-German Journal of Clinical Oncology. 5(6). 442–445. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact